Clinical translation and evidence rails are the contract research organizations, regulated software systems, biosimulation platforms, real-world-data vendors, diagnostics data assets, and safety workflows that turn an AI-generated biology idea into trial evidence a sponsor, physician, payer, or regulator can inspect. Sponsors pay through clinical study contracts, software subscriptions, data licenses, diagnostic testing, and model-informed development work. The mechanism is trial and evidence conversion: protocol design, site startup, recruitment, monitoring, safety reporting, data integrity, regulatory documentation, model credibility, and cash-backed backlog or subscription revenue. The current basket read is that IQV and VEEV have the broadest source-backed clinical and workflow exposure; MEDP and ICLR are the main trial-execution checks; CERT and TEM add specialized model-informed and clinical-genomic evidence; CRL is useful but more upstream and currently has weaker organic evidence.
What the stack is: the clinical execution, regulated workflow, data, diagnostic, and modeling layer that turns computational discovery output into human, payer, and regulator-readable evidence.
What it does: it designs protocols, starts sites, enrolls patients, monitors trials, captures safety events, validates models, cleans clinical data, licenses real-world evidence, and packages submission records.
Main pieces: contract research organization study teams, electronic trial master files, regulated cloud workflows, pharmacovigilance systems, biosimulation models, clinical-genomic databases, diagnostic labs, and audit trails.
Where it sits: operationally between discovery programs and drug approvals; physically across sponsor systems, CRO sites, clinical labs, investigator sites, regulator submissions, and payer evidence packages.
How the theme uses it: AI-originated targets, molecules, cohorts, biomarkers, and dose hypotheses need this layer before they can become trial starts, reimbursed tests, accepted models, approved labels, or recurring software/data revenue.
Terms used below: backlog is contracted clinical work not yet recognized as revenue; book-to-bill compares new awards with recognized revenue; model-informed drug development uses validated quantitative models to support dose, trial, or labeling decisions; real-world evidence uses patient data outside traditional randomized trials.
Report boundary: this node is a tactical report layer. It ranks the current value-chain basket, evidence checks, and chart provenance. Durable research, claim IDs, raw source registries, and sector thesis maintenance stay in the linked knowledge pages. Right-rail charts resolve through the local report API backed by read-only discovery daily_ohlc; static setup thresholds from the prior node build were authored through 2026-06-05 and are stale versus local bars now present through 2026-06-12.
Current Setup
Main readClinical evidence is the conversion gate for AI biology programs.
AI biology ideas need paid trials, validated models, clean data, safety records, and regulator or payer trust before they can become drug value. IQV and VEEV have the broadest direct rails; MEDP, ICLR, CERT, TEM, and CRL each test a narrower conversion point.
Signal 1Backlog and workflow revenue are the first proof.
IQV reports $34.2B of R&DS backlog; VEEV reports $730.2M of Q1 FY2027 subscription revenue.
Signal 2CRO demand is mixed.
MEDP has strong Q1 revenue but 0.88x book-to-bill; ICLR still needs clean post-restatement reporting and backlog comparability.
Signal 3Specialized evidence rails need cash proof.
CERT, TEM, and CRL are relevant, but services softness, diagnostics reimbursement, organic growth, and funding exposure cap rank.
InputAI target or molecule
Railtrial, model, data, safety
Buyersponsor, payer, regulator
Proofrevenue, backlog, acceptance
AI-enabled biology does not become drug value until it survives human evidence, validated models, clean clinical data, safety reporting, and regulatory documentation. FDA AI and Bayesian draft guidance keep the gate practical: sponsors need a clear context of use, model risk assessment, validation plan, data provenance, audit trails, and decision relevance before model output can support a drug or biologic decision. The node matters because every promising target, molecule, cohort, and diagnostic signal still has to move through trials, evidence systems, and payer or regulator trust.
IQV has the broadest direct rail because biopharma sponsors pay for R&DS trial execution, real-world evidence, health-care data, analytics, and commercial evidence work; its Q1 2026 R&DS backlog was $34.2 billion with 1.04x quarterly book-to-bill. VEEV is the most direct regulated workflow software rail, with Q1 FY2027 subscription revenue of $730.2 million and active Vault AI, Falcon, clinical, regulatory, safety, quality, and CRM workflow exposure. MEDP gives the basket a focused CRO execution benchmark, and CERT adds the most direct model-informed drug-development and biosimulation bridge. The next positive proof is book-to-bill above 1.0x, backlog conversion, Vault/Falcon adoption that becomes paid work, software bookings, and accepted model or real-world-evidence packages.
The setup can fail even if AI discovery activity rises. Sponsors can delay starts, cancel programs, reduce service scopes, or use AI productivity to lower billable labor. MEDP's Q1 book-to-bill was 0.88x; ICLR is still a scaled CRO but has a restatement, material weaknesses, and a backlog-methodology reset; CERT's Q1 services revenue fell 4% after a divestiture reset; TEM's data flywheel is still funded mostly by diagnostics and needs reimbursement and operating cash-flow proof; CRL's Q1 organic revenue and DSA organic revenue both declined. Watch cancellations, services bookings, diagnostic coverage, control remediation, and whether AI revenue remains bundled inside broader data, software, or service lines.
Charts use the selected-security right rail and the route /api/securities/{ticker}/chart?frequency=weekly&window=3y&as_of=latest. Local daily_ohlc now shows bars through 2026-06-12, so prior static setup thresholds from the 2026-06-05 node build must be refreshed before use as current trading evidence.
Basket
This basket is hand-curated from the parent theme, linked knowledge lanes, current company results, and current market-data checks. Ranking uses node economics and source-backed exposure first, then right-rail chart timing. IQV ranks first because it combines trial execution, real-world evidence, data, commercial analytics, and backlog scale. VEEV ranks second because regulated workflow software is a direct evidence rail with subscription-heavy recurring revenue. MEDP ranks above ICLR because its Q1 operating evidence has fewer reporting-control and backlog-methodology caveats, while bookings remain the live watch item.
IQVIA is the broadest clinical evidence rail because it combines CRO execution, real-world evidence, health-care data, analytics, commercial evidence, and backlog scale.
Market cap$30.28B
Next earningsJul. 28 est.
Latest qtr revenue$4.151B
Role in stack
Biopharma sponsors pay IQVIA for trial execution, patient and site services, real-world evidence, health-care data, analytics, commercial evidence, and AI-enabled workflow support. Awards convert through R&DS backlog, Commercial Solutions revenue, margin, and free cash flow.
Revenue mix
Q1 2026 revenue was 58% R&DS and 42% Commercial Solutions. AI economics are bundled inside services, data, analytics, and workflow offerings rather than separately disclosed.
Latest qtr revenue
Q1 2026 revenue was $4.151B for the quarter ended March 31, 2026; IQVIA reported R&DS revenue of $2.397B and Commercial Solutions revenue of $1.754B.
Veeva is the most direct regulated software rail because life-sciences customers use its cloud workflows to capture, audit, route, and retain clinical, safety, quality, regulatory, and commercial evidence.
Market cap$25.91B
Next earningsNot confirmed
Latest qtr revenue$882.95M
Role in stack
Life-sciences customers pay for regulated cloud software across clinical, regulatory, quality, safety, commercial, CRM, content, and data workflows. The conversion gate is R&D and Quality growth, Vault CRM migration, paid AI/Falcon adoption, and share-count quality.
Revenue mix
Q1 FY2027 revenue was led by subscription revenue of $730.2M. Local knowledge identifies R&D and Quality as the faster workflow-growth area, while Commercial Solutions remains strategically important and more contested.
Latest qtr revenue
Fiscal Q1 2027 revenue was $882.95M for the quarter ended April 30, 2026; subscription revenue was $730.2M.
Medpace is the focused CRO execution benchmark because biotech, pharma, and device sponsors use it to run full-service trials and supporting clinical-development work.
Market cap$13.53B
Next earningsJul. 20 est.
Latest qtr revenue$706.6M
Role in stack
Sponsors pay Medpace for study design, site operations, central lab, bioanalytical, imaging, ECG, biometrics, regulatory, and pharmacovigilance work. Awards convert into study starts, milestones, backlog revenue, EBITDA, and cash.
Revenue mix
Medpace reports one clinical development services segment, so customer and service-line mix are less visible than the operating metrics. The key gate is sponsor funding, cancellations, net new awards, and 2027 backlog quality.
Latest qtr revenue
Q1 2026 revenue was $706.6M for the quarter ended March 31, 2026; EBITDA was $149.4M, a 21.1% margin.
ICON is a scaled clinical outsourcing rail, but it ranks below Medpace because reporting controls, restatement history, and backlog-methodology changes still affect evidence trust.
Market cap$11.19B
Next earningsJul. 22 est.
Latest qtr revenue$2.11B
Role in stack
Large pharma and biotech sponsors pay ICON for global outsourced clinical development, trial operations, labs, biomarker work, data handling, and site services. Net business wins must convert into clean backlog, revenue, margin, and cash flow under the updated cancellation method.
Revenue mix
ICON reports outsourced development services as one operating segment. The useful read is backlog, book-to-bill, cancellations, contract estimates, control remediation, and margin recovery rather than precise service-line AI exposure.
Latest qtr revenue
MarketBeat/Fiscal.ai lists Q1 2026 revenue of $2.11B from the June 10, 2026 earnings entry; use this as a calendar-source figure until the official Q1 release is rechecked.
Certara is the most direct model-informed drug-development rail because its software and services turn quantitative models into dose, trial, and submission evidence.
Market cap$0.80B
Next earningsAug. 5 est.
Latest qtr revenue$106.9M
Role in stack
Sponsors, biopharma teams, and regulators use Certara for biosimulation, clinical pharmacology, PBPK/QSP work, model-informed development, data standards, and submission support. The conversion gate is software revenue, software bookings, services stabilization, and cash conversion after the divestiture reset.
Revenue mix
Q1 2026 revenue was $49.7M software and $57.2M services. One reportable segment limits visibility into software-versus-services margin quality.
Latest qtr revenue
Q1 2026 revenue was $106.9M for the quarter ended March 31, 2026; software grew while services declined after the portfolio reset.
Tempus is the clinical-genomic data rail because diagnostics volume can create multimodal patient data that biopharma customers use for cohorts, evidence, modeling, and trial matching.
Market cap$8.58B
Next earningsAug. 14 est.
Latest qtr revenue$348.1M
Role in stack
Providers and biopharma customers pay for diagnostics, multimodal clinical-genomic data, trial matching, data licensing, modeling, and AI-enabled workflows. The conversion gate is diagnostic coverage, ASP, data-product renewal, adjusted EBITDA, cash flow, and dilution.
Revenue mix
Q1 2026 revenue was about 75% Diagnostics and 25% Data and Applications. Diagnostics funds the data engine, but standalone AI/data economics are still partly bundled.
Latest qtr revenue
Q1 2026 revenue was $348.1M for the quarter ended March 31, 2026; Diagnostics was $261.1M and Data and Applications was $87.0M.
Charles River is an adjacent preclinical bridge because AI-discovered molecules still need safety, toxicology, and IND-enabling evidence before clinical translation begins.
Market cap$9.15B
Next earningsAug. 5 est.
Latest qtr revenue$995.8M
Role in stack
Pharma, biotech, academic, government, and device customers pay Charles River for research models, discovery work, GLP/non-GLP safety assessment, microbial solutions, biologics testing, and manufacturing support. It is relevant, but more upstream than the main clinical execution rails.
Revenue mix
2025 mix was led by Discovery and Safety Assessment at about 60% of revenue, with Research Models and Services near 21% and Manufacturing near 19%. The current gate is DSA backlog conversion and organic recovery.
Latest qtr revenue
Q1 2026 revenue was $995.8M for the quarter ended March 28, 2026; reported revenue grew while organic revenue and DSA organic revenue declined.
Basket market caps use CompaniesMarketCap pages accessed June 13, 2026. Earnings dates use MarketBeat calendar pages accessed June 13, 2026; all dates shown as estimates are not company-confirmed. VEEV's next date was not confirmed by the checked Nasdaq and MarketBeat pages, so the metric is labeled Not confirmed.
What Confirms Or Weakens
AreaWhat confirmsWhat weakens or invalidatesWatch next
1Node thesistranslation proof
What confirms
AI-supported programs move from discovery into IND, Phase 1, Phase 2, real-world evidence, model-informed, or submission workflows that require paid clinical execution, software, data, diagnostics, or safety work.
What weakens or invalidates
Programs stall before human studies, sponsors treat AI output only as internal productivity, or model evidence remains benchmark-only without trial, payer, or regulatory use.
Watch next
AI-originated trial starts
FDA meetings
accepted model packages
2Economics and backlogconversion route
What confirms
IQV, MEDP, and ICLR book-to-bill stay above 1.0x, cancellations fall, backlog converts into revenue and margin, and VEEV or CERT software bookings and subscription revenue expand.
What weakens or invalidates
Sub-1.0x book-to-bill persists, cancellations rise, services bookings decline, backlog burns faster than awards, or adjusted EBITDA and free cash flow fail to follow revenue.
Watch next
CRO awards
cancellations
software bookings
cash conversion
3Customer demandsponsor budgets
What confirms
Biotech, pharma, diagnostics, and provider customers fund study starts, data products, evidence software, model-informed work, and clinical-genomic testing despite selective credit and NIH uncertainty.
What weakens or invalidates
Delayed starts, sponsor cancellations, payer denials, lower diagnostic ASP, commercial-payer friction, or procurement pressure reduce paid usage before vendors can monetize the AI activity.
Watch next
MEDP cancellations
TEM ASP
CERT services bookings
IQV demand indicators
4Regulatory and data gateevidence trust
What confirms
FDA AI, Bayesian, real-world evidence, model-informed development, or digital health guidance becomes clearer and sponsors document context of use, validation, audit trails, data provenance, and model risk.
What weakens or invalidates
Evidence packages are rejected, provenance is weak, model drift or leakage appears, real-world data lacks fit-for-purpose documentation, or ICLR-style control problems spread to evidence trust.
Watch next
FDA guidance
MIDD meetings
BIMO findings
RWE acceptance
5Operating and supply constraintexecution capacity
What confirms
Site startup, patient recruitment, monitoring, lab throughput, safety reporting, model validation, and data-cleaning capacity support revenue without margin leakage or audit failures.
What weakens or invalidates
Labor, investigator-site constraints, study-start delays, data-integrity issues, NHP or study-cost pressure, or software implementation delays prevent revenue from converting into clean margin.
Watch next
study starts
site activity
audit findings
DSA utilization
6Stale conditionrefresh trigger
What confirms
Discovery daily_ohlc remains current, right-rail API charts resolve, and no material earnings, guidance, FDA, reimbursement, control-remediation, or financing update changes the evidence window.
What weakens or invalidates
A new trading week, Q2 release, FDA guidance update, payer coverage change, control-remediation update, financing event, or refreshed local OHLC setup levels supersede this static text.
MarketBeat earnings calendar pages for IQV, MEDP, ICLR, CERT, TEM, and CRL supplied estimated next earnings dates; MarketBeat and Nasdaq did not confirm a VEEV next earnings date in the checked pages. Accessed June 13, 2026.
CompaniesMarketCap pages supplied market-cap metrics for IQV, VEEV, MEDP, ICLR, CERT, TEM, and CRL, mostly as of June 12, 2026. Accessed June 13, 2026.
Read-only discovery coverage used DuckDB against ../discovery/data/discovery.duckdb and CLI checks discovery status IQV --json, discovery status TEM --json, and matching lineage-status calls for daily_ohlc.
All seven tickers have daily_ohlc through 2026-06-12. IQV, VEEV, MEDP, ICLR, CERT, and CRL have 1,278 daily bars from 2021-05-12. TEM has 500 daily bars from 2024-06-14, so its three-year chart starts at its public trading history.
Right-rail charts use weekly bars derived from daily_ohlc: first open, weekly high, weekly low, last close, and summed volume. The API route is /api/securities/{ticker}/chart?frequency=weekly&window=3y&as_of=latest, with a three-year visible horizon, 20-week EMA, 100-week EMA, and volume subgraph.
Static price thresholds from the prior node build were generated from data through 2026-06-05. Because local bars now extend to 2026-06-12, those thresholds are stale and must be recalculated before use as current trading evidence.
Lineage caveat: the representative IQV and TEM lineage-status calls returned older Massive ingestion runs with source freshness of 2026-05-08 even though the canonical daily_ohlc table contains bars through 2026-06-12. Treat the table coverage as current and lineage detail as incomplete until discovery lineage is reconciled.
Known Gaps
AI revenue is not separately disclosed for IQV, VEEV, TEM, or CERT in a way that supports standalone AI-margin claims.
ICLR requires post-restatement operating reports and control-remediation evidence before its backlog and margin recovery can be treated as normalized.
TEM and CRL are cross-node or adjacent exposures; TEM also belongs in diagnostics/data, and CRL also belongs in preclinical tools and DSA.
Several Q2 2026 evidence windows are near; this page should be refreshed after the next earnings and discovery update cycle.